Last update Feb. 27, 2023

Αλλοπουρινόλη

Compatible

Safe product and/or breastfeeding is the best option.

Allopurinol and its metabolite oxypurinol decrease the level of uric acid in plasma and urine by inhibiting the xanthine oxidase enzyme. Indicated for the treatment of clinical manifestations of uric acid/urate deposits, such as gout or gouty lithiasis. It has been used in Chagas disease. Oral administration.

In a mother, allopurinol was excreted in breast milk in an insignificant amount, but the levels of allopurinol were elevated. (Kamilli 1993 y 1991)

No clinical or laboratory problems were observed in two infants whose mothers was taking allopurinol (Thornley 1994, Kamilli 1993). The levels of allopurinol in the plasma of one infant were undetectable, but those of oxipurinol were almost at a therapeutic level. (Kamilli 1993 y 1991)

Allopurinol side effects are very rare and not serious. It can cause the appearance of rash. (AEMPS 2020, AA Pharma 2010)

American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001). Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)

Alternatives

  • Probenecid (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Αλλοπουρινόλη is Allopurinol in Greek.

Is written in other languages:

Group

Αλλοπουρινόλη belongs to this group or family:

Tradenames

Main tradenames from several countries containing Αλλοπουρινόλη in its composition:

List of 30 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 67 - 90 %
Molecular weight 136 daltons
Protein Binding 0 %
VD 1.6 l/Kg
pKa 8.47 -
Tmax 1.5 (oxipurinol: 4) hours
T½ 1 - 2 (oxipurinol: 15) hours
M/P ratio 0.9-1.4; oxipurinol: 2.4-3.9 -
Theoretical Dose 0.2 (+ 8 oxipurinol) mg/Kg/d
Relative Dose 4 (oxipurinol: 80) %
Ped.Relat.Dose 2 (Oxipurinol: 40-80) %

References

  1. AEMPS. Alopurinol. Ficha técnica. 2020 Full text (in our servers)
  2. AA Phama. Allopurinol. Drug Summary. 2010 Full text (in our servers)
  3. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  4. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  5. Thornley S, Manoharan A. Successful treatment of essential thrombocythemia with alpha interferon during pregnancy. Eur J Haematol. 1994 Jan;52(1):63-4. No abstract available. Abstract
  6. Kamilli I, Gresser U. Allopurinol and oxypurinol in human breast milk. Clin Investig. 1993 Abstract
  7. Kamilli I, Gresser U, Schaefer C, Zöllner N. Allopurinol in breast milk. Adv Exp Med Biol. 1991 Abstract

Total visits

609

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM